{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:32:35Z","timestamp":1790170355150,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.esmoop.2024.103696","type":"journal-article","created":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T11:26:27Z","timestamp":1725881187000},"page":"103696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study"],"prefix":"10.1016","volume":"9","author":[{"given":"C.","family":"Gallois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Bergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9.","family":"Auclin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Higu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Trouilloud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Touchefeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mazard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-0409","authenticated-orcid":false,"given":"A.","family":"Sartore-Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-7352","authenticated-orcid":false,"given":"H.","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1619-1986","authenticated-orcid":false,"given":"A.","family":"Alberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1067-1356","authenticated-orcid":false,"given":"L.","family":"Pilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cuissy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Wookey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Perret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Melchior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9777-0866","authenticated-orcid":false,"given":"P.","family":"Artru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-0423","authenticated-orcid":false,"given":"O.","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-7457","authenticated-orcid":false,"given":"A.","family":"Drouillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-5622","authenticated-orcid":false,"given":"S.","family":"Doat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-6618","authenticated-orcid":false,"given":"J.","family":"Lavol\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1457-2272","authenticated-orcid":false,"given":"D.","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3297-5801","authenticated-orcid":false,"given":"S.","family":"Stintzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-5415","authenticated-orcid":false,"given":"J.","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"D.","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9955-4753","authenticated-orcid":false,"given":"J.","family":"Taieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.esmoop.2024.103696_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","article-title":"Exploring the best treatment options for BRAF-mutant metastatic colon cancer","volume":"121","author":"Taieb","year":"2019","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103696_bib2","doi-asserted-by":"crossref","first-page":"e1331","DOI":"10.1634\/theoncologist.2018-0914","article-title":"Characteristics of BRAFV600E mutant, deficient mismatch repair\/proficient mismatch repair, metastatic colorectal cancer: a multicenter series of 287 patients","volume":"24","author":"de la Fouchardi\u00e8re","year":"2019","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.esmoop.2024.103696_bib3","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1158\/1078-0432.CCR-16-2923","article-title":"Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma","volume":"23","author":"Delord","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103696_bib4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103696_bib5","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","article-title":"Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial","volume":"17","author":"Planchard","year":"2016","journal-title":"Lancet Oncol"},{"issue":"34","key":"10.1016\/j.esmoop.2024.103696_bib6","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"7387","key":"10.1016\/j.esmoop.2024.103696_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103696_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","article-title":"Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer","volume":"8","author":"Corcoran","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.esmoop.2024.103696_bib9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","article-title":"Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation","volume":"6","author":"Hong","year":"2016","journal-title":"Cancer Discov"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103696_bib10","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1158\/1078-0432.CCR-14-2779","article-title":"Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients","volume":"21","author":"Yaeger","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.esmoop.2024.103696_bib11","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103696_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103696_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100506","article-title":"Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience","volume":"7","author":"Boccaccino","year":"2022","journal-title":"ESMO Open"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103696_bib14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2023.41.4_suppl.126","article-title":"Effectiveness and safety of encorafenib-cetuximab in BRAFV600E metastatic colorectal cancer: confidence study","volume":"41","author":"Fernandez Montes","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103696_bib15","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41416-024-02711-w","article-title":"Efficacy-effectiveness analysis on survival in a population-based real-world study of BRAF-mutated metastatic colorectal cancer patients treated with encorafenib-cetuximab","volume":"131","author":"Zwart","year":"2024","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103696_bib16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41416-021-01319-8","article-title":"Determining lines of therapy in patients with solid cancers: a proposed new systematic and comprehensive framework","volume":"125","author":"Saini","year":"2021","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.esmoop.2024.103696_bib17","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/jnci\/djab042","article-title":"BRAFV600E mutation in first-line metastatic colorectal cancer: an analysis of individual patient data from the ARCAD database","volume":"113","author":"Cohen","year":"2021","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.esmoop.2024.103696_bib18","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies","volume":"20","author":"Venderbosch","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmoop.2024.103696_bib19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.annonc.2023.08.006","article-title":"Different prognostic values of KRAS exon 2 submutations and BRAF V600E mutation in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: an ACCENT\/IDEA pooled analysis of seven trials","volume":"34","author":"Taieb","year":"2023","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2024.103696_bib20","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103696_bib21","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103696_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1634\/theoncologist.2007-0201","article-title":"Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?","volume":"13","author":"Tabernero","year":"2008","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103696_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/oncolo\/oyab030","article-title":"Efficacy and safety of cetuximab dosing (biweekly vs weekly) in patients with KRAS wild-type metastatic colorectal cancer: a meta-analysis","volume":"27","author":"Parikh","year":"2022","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.esmoop.2024.103696_bib24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2217\/fon-2023-0282","article-title":"Cetuximab every 2 weeks versus standard weekly dosing administration schedule","volume":"20","author":"Bokemeyer","year":"2023","journal-title":"Future Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103696_bib25","article-title":"BREAKWATER: an open-label, multicenter, randomized, phase 3 study, with a safety lead-in (SLI), of first-line (1L) encorafenib (E)\u00a0+ cetuximab (C) \u00b1 chemotherapy (CT) vs standard-of-care (SOC) CT for BRAF V600E-mutant metastatic colorectal cancer (mCRC)","volume":"41","author":"Kopetz","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103696_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clcc.2022.12.003","article-title":"Adverse events associated with encorafenib plus cetuximab in patients with BRAFV600E-mutant metastatic colorectal cancer: an in-depth analysis of the BEACON CRC study","volume":"22","author":"Taieb","year":"2022","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103696_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103696_bib28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2021.01.024","article-title":"Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer","volume":"147","author":"Stammler","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103696_bib29","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/jdv.15363","article-title":"The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma","volume":"33","author":"Graf","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"9","key":"10.1016\/j.esmoop.2024.103696_bib30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2022.06.002","article-title":"Fewer cetuximab-related skin-toxicities in colorectal cancer patients treated with encorafenib: a yin and yang effect of ERK paradoxical activation","volume":"33","author":"Ciccolini","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103696_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.annonc.2023.02.016","article-title":"Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments","volume":"34","author":"Ros","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103696_bib32","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1158\/1078-0432.CCR-16-0140","article-title":"BRAF V600E mutant colorectal cancer subtypes based on gene expression","volume":"23","author":"Barras","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2024.103696_bib33","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1200\/JCO.2021.39.15_suppl.3513","article-title":"Molecular correlates of clinical benefit in previously treated patients (pts) with BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study","volume":"39","author":"Kopetz","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103696_bib34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2022.03.011","article-title":"Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: an AGEO-GONO case series","volume":"168","author":"Hafliger","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2024.103696_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102996","article-title":"Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset","volume":"9","author":"Germani","year":"2024","journal-title":"ESMO Open"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103696_bib36","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1200\/JCO.2023.41.16_suppl.3589","article-title":"Overall survival of patients with BRAF-mutant metastatic colorectal cancer treated with encorafenib-cetuximab in a real-world nationwide study in the Netherlands","volume":"41","author":"van Nassau","year":"2023","journal-title":"J\u00a0Clin Oncol"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924014650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T15:35:31Z","timestamp":1727364931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924014650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2059702924014650"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103696","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103696"}}